CXR’s collaborative and advisory approach, toxicological expertise and extensive laboratory capabilities have helped customers of all sizes resolve issues relating to the safety of compounds or selection of drug or chemical candidates.
Our customers include leading pharmaceutical, agrochemical, chemical, consumer product and biotechnology companies. We provide Investigative Toxicology, Exploratory & Discovery Toxicology, and Metabolism and PK/TK services and expertise on a contract research basis.
CXR employs over 35 staff recruited from both industrial and academic backgrounds, over 30% of whom have PhDs. The combination of academic excellence together with extensive industrial experience in pharmaceutical, agrochemical and chemical toxicology, metabolism and pharmacokinetics leads to a uniquely skilled investigative toxicology and preclinical development service.
To date, we have helped over 60 companies/consortia of all sizes across a broad range of different sectors including global pharmaceutical, biotech, agrochemical, consumer product, industrial chemical and fine chemical companies. These have included: BASF, Bayer, Dow Agrochemical, DuPont, Monsanto, Syngenta, ExxonMobil, AstraZeneca, Sanofi-Aventis, Pfizer, Roche, Procter & Gamble, Cancer Research Technology, Ineos Fluor, Ineos Chlor, 3M, Plastics Europe and ECPI.
Investigative and Mechanistic Toxicology
We design and perform experiments to explain observed toxicities, and evaluate the actual hazard and risk to humans…
Exploratory and Discovery Toxicology
We use mechanistic toxicology at the research stage to drive chemical design, candidate selection and translational risk assessment…
Metabolism and PK/TK Support
CXR works with agrochemical, chemical and pharmaceutical companies to generate PK/TK, absorption and metabolic profiling data…
CXR has provided exploratory toxicology and investigative toxicology services to the agrochemical industry for many years.
Pharmaceutical & Biotech
CXR works with pharmaceutical and biotechnology companies to support discovery toxicology and investigative toxicology programs.
CXR has provided investigative toxicology, metabolism, absorption and read-across services to the chemicals industry for many years.
CXR has expertise in elucidating potential mechanisms of toxicity of marketed consumer products, & of using primary cell culture and genomics to support product claims.
New investigative toxicology research from CXR Biosciences: six posters to be co-presented at the upcoming Society of Toxicology conference in partnership with BASF, Adama, Monsanto and the H4R REACH consortium
CXR Biosciences, the investigative and exploratory toxicology company, is co-presenting six posters at the upcoming Society of Toxicology meeting in New Orleans on 13th – 17th March. This innovative research has been performed with several CXR customers including BASF, Adama, Monsanto and the H4R REACH consortium. Four posters describe studies performed at CXR to investigate […]
CXR Biosciences wins overall Business of the Year, Science and Technology Business of the Year and Growth Business of the Year at The Courier Business Awards
An outstanding year for CXR Biosciences was recognised with a triple win at the 2015 Courier Business Awards, including becoming the third winner of the coveted Business of the Year prize at the glittering Courier Business Awards ceremony at the Fairmont St Andrews.
CXR Biosciences receives French Research Tax Credit accreditation
CXR Biosciences, the investigative and exploratory toxicology company, is pleased to announce that it has received French research tax credit approval for years 2015 through to 2017.
Concept Life Sciences makes its fifth acquisition further expanding its analytical support services
Concept Life Sciences, scientific laboratory and consultancy group has acquired pharmaceutical analytical testing business Agenda1 Analytical Services Ltd (Agenda 1). This marks its fifth acquisition since it was formed in July 2014.
Concept Life Sciences acquires CXR Biosciences to augment its expanding service base in Discovery and PreClinical Sciences
CXR Biosciences, the investigative and exploratory toxicology company, has been acquired by Concept Life Sciences, the scientific laboratory and consultancy group. CXR Biosciences will retain its name and operate under the Concept Life Sciences Group umbrella. All CXR staff will be joining the Concept Life Sciences’ Group, and CXR Biosciences CEO Paul Smith will continue to head up the business. CXR will continue to provide its customers with its investigative toxicology, exploratory toxicology and metabolism and pharmacokinetics services from its laboratory base in Dundee, UK.
CXR Biosciences’ pharmaceutical discovery toxicology services summarised in new brochure publication
Preclinical toxicity remains a significant cause of compound failure during pharmaceutical development. In order to reduce the rate of compound attrition, there is an increasing emphasis on identifying and characterising potential toxicological liabilities in the discovery phase of R&D, prior to candidate selection. This discipline is generally termed discovery toxicology, and the approach and methods required differ from those required for traditional regulatory toxicology. CXR Biosciences focuses on providing discovery and investigativetoxicology services, and our discovery toxicology expertise is now conveniently summarised in a single publication.